Trusted Supply of Critical & Orphan Medicines, Worldwide!

Drug: Panitumumab
Brand: Vectibix 100mg/5ml
Manufacturer /
TM Owner
Amgen
Origin: USA

Vectibix 100mg/5ml Vial

Vectibix delivers Panitumumab as a monoclonal antibody. It binds precisely to a disease-driving target, blocking harmful signalling or flagging abnormal cells for immune destruction. It is used in the treatment of colorectal cancer. It is supplied as a vial (100mg/5ml). Its targeted profile makes it a valued choice in contemporary clinical practice.
Strength: 100mg/5ml
Pack Size: 1s
Storage: 2°C to 8°C
Form: Vial

+91 900 500 9556

Global Shipping : Reliable Global Distribution Network

Express Delivery : Priority Shipping for Every Order

Secure Payments : Trusted Payment Protection System

Disclaimer
All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the 'Manufacturer/ TM Owner' section in compliance with statutory requirements. Read More

Secure Handling

24/7 Worldwide Support

Global Access

Worldwide Access to Health

Cold-Chain Expert

Excellence in Cold-Chain

Trusted Supply

Certified Medical Supply

Indications & Clinical Uses

  • Vectibix 100 mg/5 mL (20 mg/mL) is a single-dose vial of panitumumab, a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR), used to treat metastatic colorectal cancer in adults.
  • In the US label it is approved for wild-type RAS tumours, either as first-line treatment with FOLFOX chemotherapy or as a single agent after earlier chemotherapy, and, together with sotorasib, for KRAS G12C-mutated tumours after prior treatment.
  • Vectibix is given only by a healthcare provider, in a clinic or hospital, as an intravenous infusion of 6 mg/kg every 14 days, over 60 minutes for doses up to 1000 mg and over 90 minutes for larger doses.
  • A 400 mg/20 mL vial of the same 20 mg/mL concentration also exists, so the dose is calculated by bodyweight, not by vial.
  • Vectibix is marketed by Amgen Inc.

Side Effects

  • BOXED WARNING: dermatologic toxicity.
  • Skin reactions occurred in about 90% of patients and were severe (grade 3 or higher) in 15% of those receiving Vectibix alone.
  • Common effects (20% or more) of Vectibix alone are rash, paronychia (nail-fold infection), fatigue, nausea and diarrhoea.
  • With FOLFOX, diarrhoea (62%), mouth sores, mucosal inflammation, weakness, poor appetite, low magnesium and potassium, and acne-like rash are common; with sotorasib, rash (87%), dry skin, diarrhoea, mouth sores, fatigue and musculoskeletal pain.
  • Infusion reactions occurred in 4% of patients (1% severe).
  • Serious effects include lung inflammation or scarring (interstitial lung disease), low magnesium and potassium (in 38 to 76%), and eye problems such as keratitis and corneal perforation.
  • Tell your care team at once about worsening rash, cough or breathlessness, eye pain or redness, or any reaction during the infusion.

Precautions & Warnings

  • Vectibix has a boxed warning for dermatologic toxicity: your skin will be checked, and treatment may be paused, reduced or permanently stopped for severe (grade 3 or 4) reactions.
  • Blood magnesium and potassium are monitored and replaced when low.
  • The infusion rate is reduced by 50% for mild to moderate infusion reactions and the infusion is stopped for severe ones.
  • Treatment is discontinued if interstitial lung disease is confirmed, and eye symptoms need prompt review.
  • Vectibix can cause fetal harm: use effective contraception during treatment and for 2 months after the last dose, and avoid breastfeeding for the same period.
  • Use sun protection during treatment and for 2 months afterwards because of photosensitivity.
  • No contraindications are listed in the US label.
  • Vials are kept by the pharmacy at 2°C to 8°C, in the carton, protected from light, never frozen or shaken.

Avoid Interactions

  • Increase effect or toxicity: do not combine Vectibix with bevacizumab plus chemotherapy, because this increased mortality and grade 3 to 5 toxicity (87% versus 72%) in trials.
  • Sun exposure raises the risk of photosensitivity skin reactions.
  • When Vectibix is given with sotorasib, dose interruptions are coordinated between the two medicines, and with FOLFOX chemotherapy the side effects of both apply.
  • Reduce efficacy: the sections of the label reviewed did not identify specific interacting drugs that reduce its effect.
  • Tell your oncology team about all prescription medicines, over-the-counter products, herbal remedies and supplements.
  • Vectibix must not be frozen or shaken, and unused vial contents are discarded.

References

Frequently Asked Questions

Vectibix (panitumumab) treats metastatic colorectal cancer in adults. In the US it is used for wild-type RAS tumours, with FOLFOX chemotherapy first or alone after earlier chemotherapy, and with sotorasib for KRAS G12C-mutated tumours after prior treatment. A healthcare provider gives it by infusion.

Simple Working Process

We have simplified the online drug ordering process into 4 easy steps to ensure
a safe, secure, and hassle-free experience for our customers.


Order Online

Place your order online and upload prescription in minutes with ease.



Order Confirmation

We verify your prescription and confirm your order quickly and securely.



Prescription Review

Reviewed by licensed pharmacists. Carefully processed and validated.

R

Receive Medicines

Approved order delivered fast, easy, and right to your doorstep or nearby Airport.



Global Standards. Trusted Care.

Trusted & Reliable – Your Partner in Global Distribution.

We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.